Lombard Medical Technologies announced that it has halted patient enrollment for a U.S. clinical study of EndoRefix, a graft-fixation device, to reduce expenses. The firm said it is still in talks "with potential investors and expects to update the market on developments in due course."

Full Story:

Related Summaries